Literature DB >> 22977276

Risk factors for coronary heart disease and survival after myocardial infarction.

Sjoerd T Nauta1, Jaap W Deckers, Robert M van der Boon, K Martijn Akkerhuis, Ron T van Domburg.   

Abstract

OBJECTIVES: Several risk factors for coronary heart disease (CHD) have been associated with improved in-hospital survival after myocardial infarction (MI). We aimed to confirm this paradox and assess whether it extends to long-term outcome. In addition, we investigated temporal mortality trends.
METHODS: We examined the relation between the presence of four modifiable risk factors for CHD (hypertension, dyslipidaemia, diabetes mellitus and smoking) and mortality in 14,434 consecutive patients admitted with MI to a coronary care unit from 1985 to 2008.
RESULTS: Two-thirds of MI patients (n = 10,003) had at least one risk factor for CHD on hospital admission. The presence of at least one compared to no CHD risk factors was associated with a favourable 30-day mortality rate (5% vs. 7%, adjusted odds ratio 0.72, 95% confidence interval (CI): 0.62-0.83). There was significant interaction between the presence of CHD risk factors and decade of hospitalization (p = 0.001). The adjusted 10-year mortality hazard ratio (HR) of at least one CHD risk factor compared to none, was 1.2 (95% CI: 1.0--1.4), 0.89 (0.65--1.2) and 0.89 (0.79--0.99) in 1985--1990, 1990--2000 and 2000--2008, respectively. Survival improved over time. Adjusted 10-year mortality fell (adjusted HR [2000--2008 vs. 1985--1990] 0.59 [95% CI: 0.52--0.66] in patients with, and 0.76 [95% CI: 0.65-0.89] in those without CHD risk factors).
CONCLUSIONS: The presence of at least one modifiable CHD risk factor was associated with improved outcome after MI. Patients with CHD risk factors benefited from more substantial mortality reductions during the past few decades.

Entities:  

Keywords:  Mortality; NSTEMI; STEMI; coronary heart disease; diabetes; hyperlipidaemia; hypertension; long-term survival; paradox; smoking

Mesh:

Year:  2012        PMID: 22977276     DOI: 10.1177/2047487312460514

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  9 in total

1.  Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Authors:  Ariadna Contreras; Aaron F Orozco; Micheline Resende; Robert C Schutt; Jay H Traverse; Timothy D Henry; Dejian Lai; John P Cooke; Roberto Bolli; Michelle L Cohen; Lem Moyé; Carl J Pepine; Phillip C Yang; Emerson C Perin; James T Willerson; Doris A Taylor
Journal:  Basic Res Cardiol       Date:  2016-11-23       Impact factor: 17.165

2.  Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study.

Authors:  Dirk Westermann; Shaun G Goodman; José C Nicolau; Gema Requena; Andrew Maguire; Ji Yan Chen; Christopher B Granger; Richard Grieve; Stuart J Pocock; Stefan Blankenberg; Ana Maria Vega; Satoshi Yasuda; Tabassome Simon; David Brieger
Journal:  Clin Cardiol       Date:  2017-12-16       Impact factor: 2.882

3.  A Swine Model of Percutaneous Intracoronary Ethanol Induced Acute Myocardial Infarction and Ischemic Mitral Regurgitation.

Authors:  Weiwei Shi; Bryant V McIver; Kanika Kalra; Eric L Sarin; Susan Schmarkey; Michael Duggan; Vinod H Thourani; Robert A Guyton; Muralidhar Padala
Journal:  J Cardiovasc Transl Res       Date:  2017-06-02       Impact factor: 4.132

4.  International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee.

Authors:  Yejin Mok; Shoshana H Ballew; Lori D Bash; Deepak L Bhatt; William E Boden; Marc P Bonaca; Juan Jesus Carrero; Josef Coresh; Ralph B D'Agostino; C Raina Elley; F Gerry R Fowkes; Sun Ha Jee; Csaba P Kovesdy; Kenneth W Mahaffey; Girish Nadkarni; Eric D Peterson; Yingying Sang; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2018-07-07       Impact factor: 5.501

5.  Cardiovascular magnetic resonance characteristics and clinical outcomes of patients with ST-elevation myocardial infarction and no standard modifiable risk factors-A DANAMI-3 substudy.

Authors:  Jawad Mazhar; Kathrine Ekström; Rebecca Kozor; Stuart M Grieve; Lars Nepper-Christensen; Kiril A Ahtarovski; Henning Kelbæk; Dan E Høfsten; Lars Køber; Niels Vejlstrup; Stephen T Vernon; Thomas Engstrøm; Jacob Lønborg; Gemma A Figtree
Journal:  Front Cardiovasc Med       Date:  2022-08-03

6.  American Heart Association's Life's Simple 7 at Middle Age and Prognosis After Myocardial Infarction in Later Life.

Authors:  Yejin Mok; Yingying Sang; Shoshana H Ballew; Casey M Rebholz; Wayne D Rosamond; Gerardo Heiss; Aaron R Folsom; Josef Coresh; Kunihiro Matsushita
Journal:  J Am Heart Assoc       Date:  2018-02-17       Impact factor: 5.501

7.  Improving Outcomes After Myocardial Infarction in the US Population.

Authors:  Waleed T Kayani; Christie M Ballantyne
Journal:  J Am Heart Assoc       Date:  2018-02-17       Impact factor: 5.501

8.  Predictors of all-cause 1-year mortality in myocardial infarction patients.

Authors:  Qing Ye; Jie Zhang; Likun Ma
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

9.  Progression of coronary atherosclerosis in patients without standard modifiable risk factors.

Authors:  Jawad Mazhar; Gemma Figtree; Stephen T Vernon; Keyvan Karimi Galougahi; Julie Carlo; Steven E Nissen; Stephen J Nicholls
Journal:  Am J Prev Cardiol       Date:  2020-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.